3D-QSAR and docking studies on pyridopyrazinones as BRAF inhibitors
- 28 October 2010
- journal article
- research article
- Published by Springer Nature in Medicinal Chemistry Research
- Vol. 20 (8) , 1298-1317
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- BRAF Inhibitors Based on an Imidazo[4,5]pyridin-2-one Scaffold and a Meta Substituted Middle RingJournal of Medicinal Chemistry, 2010
- CoMFA and CoMSIA analyses on 4-oxo-1,4-dihydroquinoline and 4-oxo-1,4-dihydro-1,5-, -1,6- and -1,8-naphthyridine derivatives as selective CB2 receptor agonistsJournal of Molecular Modeling, 2009
- Novel Potent BRAF Inhibitors: Toward 1 nM Compounds through Optimization of the Central Phenyl RingJournal of Medicinal Chemistry, 2009
- Pyridoimidazolones as Novel Potent Inhibitors of v-Raf Murine Sarcoma Viral Oncogene Homologue B1 (BRAF)Journal of Medicinal Chemistry, 2009
- Predicting anti-HIV activity of 1,1,3-trioxo[1,2,4]-thiadiazine (TTD) derivatives: 3D QSAR approachMedicinal Chemistry Research, 2009
- Acylthiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors: docking studies and ligand-based CoMFA and CoMSIA analysesJournal of Molecular Modeling, 2009
- Pharmacophore based 3D-QSAR study of VEGFR-2 inhibitorsMedicinal Chemistry Research, 2008
- MAP kinase signalling pathways in cancerOncogene, 2007
- MAPKs: function, regulation, role in cancer and therapeutic targetingOncogene, 2007
- Melanoma biology and new targeted therapyNature, 2007